Ipamorelin Research Timeline: Key Studies and Milestones

Vintage laboratory scientist — the early era of the Ipamorelin research timeline

The Ipamorelin research timeline runs from the early-1980s discovery of growth-hormone-releasing peptides, through a landmark 1998 paper that introduced ipamorelin as the first selective growth hormone secretagogue, to Phase 2 clinical trials and the compound’s current life as a research tool. This chronological history of the Ipamorelin research timeline covers the key studies and milestones in the order they happened — a literature history, not an efficacy story, and strictly in research framing.

Research-use-only disclaimer: Ipamorelin is not an FDA-approved drug and is not a medicine. It is handled as a research compound for laboratory and scientific investigation only. This article is an educational history of the published literature. It contains no dosage information, no usage instructions, and no medical advice.

How to Read the Ipamorelin Research Timeline

A research timeline is a map of what was studied and published, not a ladder of increasing proof that a compound “works.” Some entries below are chemistry papers, some are animal studies, one is a discontinued clinical program — each belongs for a different reason. The Ipamorelin research timeline is most useful when every milestone is read for what it actually contributed: a structure, a mechanism, a dataset, or a decision.

1980s–1996: The Road to Ipamorelin

The Ipamorelin research timeline begins before ipamorelin existed. In the late 1970s and early 1980s, Cyril Bowers and colleagues developed a series of synthetic opioid-peptide derivatives that potently stimulated growth hormone (GH) release from the anterior pituitary — the growth-hormone-releasing peptides (GHRPs), including GHRP-6. These compounds acted independently of the known GH-releasing hormone (GHRH) pathway, which pointed to an undiscovered receptor system.

Through the early 1990s, researchers characterized that system: a pituitary GHRP receptor subtype was identified by photoaffinity labeling (1994), and in 1996 Howard and colleagues cloned the receptor itself — a seven-transmembrane G-protein-coupled receptor that became known as the growth hormone secretagogue receptor, GHS-R (later GHSR-1a). The receptor was an “orphan”: its natural ligand was still unknown. Into this gap stepped the medicinal chemists at Novo Nordisk, who were systematically building novel GHRP-receptor-active compounds — the program that would produce ipamorelin.

Chemist handling laboratory equipment — medicinal chemistry era of the Ipamorelin research timeline
Photo: Wikimedia Commons

1998: The Landmark Paper in the Ipamorelin Research Timeline

November 1998 is the pivotal date in the Ipamorelin research timeline. Raun, Hansen, Johansen, Thøgersen, Madsen, Ankersen, and Andersen — the Novo Nordisk team — published “Ipamorelin, the first selective growth hormone secretagogue” in the European Journal of Endocrinology (139(5):552–561).

Raun et al., 1998 — what the paper established. Ipamorelin (development code NNC 26-0161), a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 derived from GHRP-1, released GH with high potency and efficacy without significant effects on plasma ACTH or cortisol — unlike earlier secretagogues such as GHRP-6 and GHRP-2, which also raised prolactin and cortisol. The authors concluded it was the most selective GHRP-receptor-active GH secretagogue described to that point. Selectivity — GH release without the collateral pituitary hormones — became ipamorelin’s defining research property, and the one most cited across the Ipamorelin research timeline.

The same chemistry program published companion work in 1998 (Hansen et al., Journal of Medicinal Chemistry) on novel orally active GH secretagogues, situating ipamorelin within a broader Novo Nordisk medicinal-chemistry campaign. For the Ipamorelin research timeline, 1998 is year zero: the compound goes from patent-series prototype to named, published research tool.

1999–2005 in the Ipamorelin Research Timeline: Bone, Pituitary, Ghrelin

The years after the landmark paper did two things: extended ipamorelin’s pharmacology into new tissues, and — via an unrelated discovery — explained what its receptor was actually for — the next chapter of the Ipamorelin research timeline.

YearStudyContribution to the timeline
1999Johansen et al., Growth Hormone & IGF ResearchIpamorelin induces longitudinal bone growth in rats — first skeletal endpoint
1999Kojima & Kangawa discover ghrelinEndogenous ligand of GHS-R1a identified; ipamorelin reframed as a ghrelin mimetic
2000Svensson et al.Ipamorelin and GHRP-6 increase bone mineral content in adult female rats
2002Jiménez-Reina et al., Histology & HistopathologyChronic ipamorelin treatment: somatotroph response in young female rats
2004Holst & Schwartz, EndocrinologyGhrelin receptor mutations and ligand selectivity — mechanistic context
2005Smith et al., Endocrine ReviewsMajor review of GH secretagogue physiology and mechanisms

The 1999 ghrelin discovery deserves emphasis in any Ipamorelin research timeline. When Kojima and colleagues isolated the 28-amino-acid stomach hormone ghrelin as the endogenous ligand of GHS-R1a (see the PMC review at PMC4443295), every synthetic secretagogue — including ipamorelin — was retrospectively understood as a ghrelin mimetic. The compound’s selectivity profile (GH without ACTH/cortisol) now had a physiological reference point: it mimicked part of ghrelin’s signaling while sparing other pituitary axes. Later reviews, including Holst and Schwartz’s 2014 survey of GHSR signaling, kept ipamorelin in the literature as the exemplar of a selective synthetic agonist.

Pipetting culture media — laboratory methods across the Ipamorelin research timeline
Photo: Wikimedia Commons

2008–2016: The Postoperative Ileus Chapter of the Ipamorelin Research Timeline

The most clinically advanced chapter of the Ipamorelin research timeline began with a repurposing idea: ghrelin-receptor stimulation promotes motility in the upper and lower gastrointestinal tract, so a selective ghrelin mimetic might treat postoperative ileus — the temporary halt of bowel function after abdominal surgery. Helsinn Therapeutics picked up development.

2008 — Rodent proof of concept. Raun and colleagues publish ipamorelin’s efficacy in a rodent model of postoperative ileus (Journal of Surgical Research), establishing the preclinical rationale.

2012 — Gastric dysmotility mechanism. Greenwood-Van Meerveld and colleagues publish in the Journal of Experimental Pharmacology (PMC PMC4863553): in rats with surgery-induced delayed gastric emptying, intravenous ipamorelin at two tested doses reduced the delay dose-dependently, with the higher dose bringing gastric emptying close to non-surgery control levels. Follow-up work in 2016 extended the GI-motility findings.

2014 — The Phase 2 trial. The proof-of-concept, multicenter, double-blind, placebo-controlled Phase 2 study (ClinicalTrials.gov NCT00672074) enrolled 117 bowel-resection patients; 114 formed the safety and modified intent-to-treat populations. Patients received intravenous ipamorelin or placebo twice daily from postoperative day 1 to day 7 or discharge. The key endpoint — time to first tolerated standardized solid meal — was 25.3 hours (ipamorelin) versus 32.6 hours (placebo), a difference that did not reach statistical significance (p = 0.15). The compound was well tolerated, but efficacy was not demonstrated.

Why the program ended. Following the Phase 2 results, Helsinn discontinued ipamorelin’s development for postoperative ileus due to lack of efficacy — a matter of public record (Ipamorelin). A second completed Phase 2 entry (NCT01280344, gastrointestinal dysmotility) appears in DrugBank’s trial records. In the Ipamorelin research timeline, this chapter is instructive: a compound can have an elegant pharmacology, a real receptor, and promising animal data — and still not clear a human efficacy bar. That is what clinical testing is for.

The Ipamorelin Research Timeline Today

After the Helsinn program closed, the Ipamorelin research timeline entered its current phase: the compound as a research tool rather than a drug candidate. It is not an approved pharmaceutical anywhere; it is widely marketed and used as a research peptide. In the literature, it persists in three roles: as the reference selective GHSR-1a agonist in receptor-pharmacology studies, as a comparator in ghrelin-mimetic GI research, and as a GH-axis probe in endocrine studies. Our Selank vs Semax comparison shows how other research peptides occupy similar post-development niches in the literature.

Cell culture bioreactor — modern laboratory research in the Ipamorelin research timeline
Photo: Wikimedia Commons

Ipamorelin Research Timeline at a Glance

PeriodMilestoneSignificance
Early 1980sBowers group develops GHRPsSynthetic GH secretagogues discovered
1996GHS receptor clonedMolecular target identified (orphan receptor)
1998Raun et al.: ipamorelin describedFirst selective GH secretagogue; NNC 26-0161
1999Ghrelin discovered; bone-growth studyEndogenous ligand found; skeletal effects shown
2000–2005Bone, pituitary, and review literaturePharmacology broadened and consolidated
2008–2012Postoperative ileus preclinical workRepurposing rationale built (Helsinn)
2014Phase 2 trial NCT00672074Well tolerated; efficacy not demonstrated
2014–presentDevelopment discontinuedCompound continues as a research tool

Ipamorelin Research Timeline: Key Takeaways

1998 is the founding date of the Ipamorelin research timeline: Raun et al. introduced ipamorelin (NNC 26-0161) as the first selective growth hormone secretagogue — GH release without significant ACTH or cortisol effects.

1999 reframed everything: the discovery of ghrelin as the endogenous GHS-R1a ligand turned ipamorelin into a understood ghrelin mimetic rather than an orphan-receptor agonist.

The clinical chapter is complete and closed: Helsinn’s Phase 2 program for postoperative ileus (NCT00672074) showed tolerability without significant efficacy, and development was discontinued.

The compound lives on as a research tool — the reference selective GHSR-1a agonist in receptor pharmacology and GH-axis research.

Research framing only — this timeline describes published literature. It is not medical advice and makes no claim about human use.

Conclusion

The Ipamorelin research timeline is, in the end, a complete little history of modern peptide science: a receptor found before its ligand, a medicinal-chemistry campaign that produced a genuinely selective tool compound, a decade of productive pharmacology, a serious clinical attempt at a real medical problem, and an honest negative result that closed the development chapter. Few research peptides get all five acts; ipamorelin got them, and the literature is better for it.

For researchers, the timeline’s value is practical: it shows exactly what “selective” meant in 1998, why the compound mattered to ghrelin biology after 1999, and what the Phase 2 data did and did not show. For wider reading in the same evidence-first style, see our Selank vs Semax research comparison and our research overviews of Semax and Selank nasal spray formats. The Ipamorelin article on Wikipedia offers a compact reference for the compound’s chemistry and development status.

Biosafety cabinet with microscope — controlled research environments in the Ipamorelin research timeline
Photo: Wikimedia Commons

Ipamorelin Research Timeline: Frequently Asked Questions

Direct answers to the questions researchers ask most about the Ipamorelin research timeline.

When was ipamorelin first described?

In November 1998 — the founding moment of the Ipamorelin research timeline — by Raun and colleagues at Novo Nordisk in the European Journal of Endocrinology (139(5):552–561), in the paper “Ipamorelin, the first selective growth hormone secretagogue.” The compound’s development code was NNC 26-0161.

What made ipamorelin “selective”?

Unlike earlier GH secretagogues (GHRP-6, GHRP-2), ipamorelin released growth hormone with high potency without significantly raising ACTH, cortisol, prolactin, FSH, LH, or TSH — a selectivity profile closer to GHRH itself. That selectivity was the paper’s central claim and the compound’s defining research property.

Was ipamorelin ever tested in humans?

Yes — the clinical chapter of the Ipamorelin research timeline. Helsinn Therapeutics ran Phase 2 trials for postoperative ileus, including the registered proof-of-concept study NCT00672074 (117 enrolled bowel-resection patients). Ipamorelin was well tolerated, but the primary efficacy endpoint did not reach statistical significance, and development was discontinued for lack of efficacy.

What is the connection between ipamorelin and ghrelin?

Ghrelin, discovered in 1999 by Kojima and Kangawa, is the endogenous ligand of the growth hormone secretagogue receptor (GHSR-1a) — the same receptor ipamorelin activates. Ipamorelin is therefore described as a ghrelin mimetic: a synthetic compound acting through the body’s ghrelin signaling pathway (PubMed 22074955).

Is ipamorelin FDA-approved?

No. Ipamorelin is not an FDA-approved drug and was never approved as a pharmaceutical. It is handled as a research compound for laboratory investigation only. The FDA’s drug information pages explain what approval status involves.

Where can researchers source peptides for endocrine research?

Research peptides are supplied as laboratory research materials — for example, our Semax 10mg and Selank 10mg research listings. Sourcing should be limited to suppliers that are explicit about research-use-only status. Nothing here is a recommendation for human use.

Leave a Comment

Cart0
Cart0

Research Verification Required

This website contains research compounds available exclusively for qualified researchers and laboratory professionals. By entering, you confirm: